SECTORAL ASSET MANAGEMENT INC
13F Reported Value
ⓘ$143.3M
Holdings
82
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
SECTORAL ASSET MANAGEMENT INC disclosed 82 positions worth $143.3M in its Form 13F-HR for Q2 2026, led by $CTNM (Contineum Therapeutics, Inc.) at 8.3% of the equity portfolio, followed by $SI and $LLY. During the quarter the fund opened 14 new positions and exited 9 — including a new stake in $ORKA and a full exit from $EVMN. The portfolio is most concentrated in Healthcare (96.6% of disclosed assets). All figures are sourced directly from SECTORAL ASSET MANAGEMENT INC’s Form 13F-HR filing with the SEC under CIK 1274413.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$11.9M727,587 sh - 29.5#2,529
Quality
$8.7M430,407 sh - 87.5#2
Quality
$7.6M6,354 sh - 62.7
Quality
$5.5M13,235 sh - 69.0
Quality
$4.6M18,218 sh - —
Quality
$4.0M41,987 sh - —
Quality
$3.9M41,869 sh - —
Quality
$3.7M78,310 sh - 76.0
Quality
$3.4M50,756 sh - 8.5
Quality
$3.4M110,870 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Contineum Therapeutics, Inc.$CTNM | — | $11.9M | 727,587 |
 SHOULDER INNOVATIONS, INC.$SI | 29.5#2,529 | $8.7M | 430,407 |
 ELI LILLY & Co$LLY | 87.5#2 | $7.6M | 6,354 |
 UNITEDHEALTH GROUP INC$UNH | 62.7 | $5.5M | 13,235 |
 JOHNSON & JOHNSON$JNJ | 69.0 | $4.6M | 18,218 |
 Oruka Therapeutics, Inc.$ORKA | — | $4.0M | 41,987 |
 BioNTech SE$BNTX | — | $3.9M | 41,869 |
 Definium Therapeutics, Inc.$DFTX | — | $3.7M | 78,310 |
 DEXCOM INC$DXCM | 76.0 | $3.4M | 50,756 |
 Arcus Biosciences, Inc.$RCUS | 8.5 | $3.4M | 110,870 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of SECTORAL ASSET MANAGEMENT INC's 82 positions.
Showing top 10 of 82 holdings.
Sector Allocation
Healthcare
$138.4M
Technology
$4.9M
Full Holdings — SECTORAL ASSET MANAGEMENT INC (Q2 2026)
All 82 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CTNM | Contineum Therapeutics, Inc. | $11.9M | 8.3% | +0% | — |
| 2 | $SI | SHOULDER INNOVATIONS, INC. | $8.7M | 6.1% | +0% | 29.5 |
| 3 | $LLY | ELI LILLY & Co | $7.6M | 5.3% | +0% | 87.5 |
| 4 | $UNH | UNITEDHEALTH GROUP INC | $5.5M | 3.8% | -12% | 62.7 |
| 5 | $JNJ | JOHNSON & JOHNSON | $4.6M | 3.2% | +0% | 69 |
| 6 | $ORKA | Oruka Therapeutics, Inc. | $4.0M | 2.8% | NEW | — |
| 7 | $BNTX | BioNTech SE | $3.9M | 2.7% | +89% | — |
| 8 | $DFTX | Definium Therapeutics, Inc. | $3.7M | 2.6% | NEW | — |
| 9 | $DXCM | DEXCOM INC | $3.4M | 2.4% | +118% | 76 |
| 10 | $RCUS | Arcus Biosciences, Inc. | $3.4M | 2.4% | +146% | 8.5 |
| 11 |  $AMGN | AMGEN INC | $3.3M | 2.3% | +0% | 79.2 |
| 12 |  $SMMT | Summit Therapeutics Inc. | $3.2M | 2.2% | +216% | — |
| 13 |  $IRTC | iRhythm Holdings, Inc. | $3.1M | 2.2% | NEW | 54.8 |
| 14 |  $ABBV | AbbVie Inc. | $3.1M | 2.1% | +0% | 72.6 |
| 15 |  $MRK | Merck & Co., Inc. | $2.8M | 1.9% | +0% | 59.9 |
| 16 |  $AVBP | ArriVent BioPharma, Inc. | $2.7M | 1.9% | +163% | — |
| 17 |  $VRTX | VERTEX PHARMACEUTICALS INC / MA | $2.7M | 1.9% | -22% | 75.4 |
| 18 |  $ARGX | ARGENX SE | $2.6M | 1.8% | -21% | — |
| 19 |  $GILD | GILEAD SCIENCES, INC. | $2.6M | 1.8% | -25% | 57.4 |
| 20 |  $INSM | INSMED Inc | $2.5M | 1.7% | +18% | 39.4 |
| 21 |  $TECX | Tectonic Therapeutic, Inc. | $2.4M | 1.7% | +273% | — |
| 22 |  $ISRG | INTUITIVE SURGICAL INC | $2.3M | 1.6% | +11% | 79.9 |
| 23 |  $IMTX | Immatics N.V. | $2.3M | 1.6% | +237% | — |
| 24 |  $SYK | STRYKER CORP | $2.2M | 1.6% | +21% | 72.1 |
| 25 |  $AVTX | Avalo Therapeutics, Inc. | $2.2M | 1.6% | NEW | 11.7 |
| 26 |  $CBIO | CRESCENT BIOPHARMA, INC. | $2.2M | 1.5% | NEW | 9.6 |
| 27 |  $ROIV | Roivant Sciences Ltd. | $2.2M | 1.5% | +88% | — |
| 28 |  $IQV | IQVIA HOLDINGS INC. | $2.1M | 1.5% | +31% | 61.4 |
| 29 |  $PLSE | PULSE BIOSCIENCES, INC. | $1.9M | 1.3% | NEW | — |
| 30 |  $DHR | DANAHER CORP /DE/ | $1.8M | 1.3% | +0% | 64.8 |
| 31 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $1.8M | 1.2% | +0% | 65.1 |
| 32 |  $ABT | ABBOTT LABORATORIES | $1.6M | 1.1% | -29% | 65.5 |
| 33 |  $ATEC | Alphatec Holdings, Inc. | $1.6M | 1.1% | NEW | 43.3 |
| 34 |  $BSX | BOSTON SCIENTIFIC CORP | $1.6M | 1.1% | +4% | 77.5 |
| 35 |  $TMDX | TransMedics Group, Inc. | $1.5M | 1.0% | NEW | 67.2 |
| 36 |  $CYTK | CYTOKINETICS INC | $1.4M | 1.0% | +124% | 28.1 |
| 37 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $1.4M | 0.9% | -26% | 71 |
| 38 |  $CVS | CVS HEALTH Corp | $1.3M | 0.9% | NEW | 59.4 |
| 39 |  $EW | Edwards Lifesciences Corp | $1.3M | 0.9% | -14% | 69.4 |
| 40 |  $TRVI | Trevi Therapeutics, Inc. | $1.2M | 0.8% | -12% | — |
| 41 |  $BMY | BRISTOL MYERS SQUIBB CO | $1.2M | 0.8% | +0% | 70.4 |
| 42 |  $VERA | Vera Therapeutics, Inc. | $1.1M | 0.8% | +0% | — |
| 43 |  $COGT | Cogent Biosciences, Inc. | $1.0M | 0.7% | +21% | — |
| 44 |  $MDT | Medtronic plc | $876,345 | 0.6% | +0% | 68.7 |
| 45 |  $TARS | Tarsus Pharmaceuticals, Inc. | $836,158 | 0.6% | +18% | 55 |
| 46 |  $KURA | Kura Oncology, Inc. | $784,136 | 0.6% | +0% | 27.6 |
| 47 |  $CNC | CENTENE CORP | $770,280 | 0.5% | NEW | 58.2 |
| 48 |  $UTHR | UNITED THERAPEUTICS Corp | $742,307 | 0.5% | -20% | 71.3 |
| 49 |  $HNGE | Hinge Health, Inc. | $725,752 | 0.5% | -29% | 74.9 |
| 50 |  $NKTR | NEKTAR THERAPEUTICS | $705,849 | 0.5% | -7% | 9.7 |
| 51 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $695,379 | 0.5% | +0% | 71.4 |
| 52 |  $ASND | Ascendis Pharma A/S | $685,470 | 0.5% | -8% | 44.8 |
| 53 |  $PFE | PFIZER INC | $662,200 | 0.5% | +0% | 62 |
| 54 |  $ARDX | ARDELYX, INC. | $624,209 | 0.4% | +0% | 41.9 |
| 55 |  $PRVA | Privia Health Group, Inc. | $621,019 | 0.4% | -11% | 60.1 |
| 56 |  $PTCT | PTC THERAPEUTICS, INC. | $609,328 | 0.4% | +12% | 35.4 |
| 57 |  $IONS | IONIS PHARMACEUTICALS INC | $570,888 | 0.4% | +0% | 23.4 |
| 58 |  $AGMB | Agomab Therapeutics NV | $564,630 | 0.4% | +0% | — |
| 59 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $540,729 | 0.4% | +0% | 58.2 |
| 60 |  $ONC | BeOne Medicines Ltd. | $532,894 | 0.4% | +0% | — |
| 61 |  $HUM | HUMANA INC | $497,299 | 0.3% | NEW | 58.9 |
| 62 |  $JAZZ | Jazz Pharmaceuticals plc | $421,698 | 0.3% | +0% | — |
| 63 |  $RPRX | Royalty Pharma plc | $403,704 | 0.3% | +0% | — |
| 64 |  $BIIB | BIOGEN INC. | $399,711 | 0.3% | +0% | 64.7 |
| 65 |  $MLYS | Mineralys Therapeutics, Inc. | $392,964 | 0.3% | -54% | — |
| 66 |  $ILMN | ILLUMINA, INC. | $374,870 | 0.3% | +0% | 60.4 |
| 67 |  $AXSM | Axsome Therapeutics, Inc. | $367,155 | 0.3% | +0% | 40.8 |
| 68 |  $SNDX | Syndax Pharmaceuticals Inc | $342,765 | 0.2% | -51% | 33.8 |
| 69 |  $RVMD | Revolution Medicines, Inc. | $342,722 | 0.2% | +0% | — |
| 70 |  $ABVX | Abivax S.A. | $311,828 | 0.2% | +0% | — |
| 71 |  $BBIO | BridgeBio Pharma, Inc. | $305,368 | 0.2% | -49% | 36.9 |
| 72 |  $MRNA | Moderna, Inc. | $304,631 | 0.2% | +0% | 21.2 |
| 73 |  $GH | Guardant Health, Inc. | $297,059 | 0.2% | +0% | 39 |
| 74 |  $INCY | INCYTE CORP | $266,396 | 0.2% | +0% | 77.4 |
| 75 |  $ORIC | Oric Pharmaceuticals, Inc. | $254,505 | 0.2% | +0% | — |
| 76 |  $SPRY | ARS Pharmaceuticals, Inc. | $239,499 | 0.2% | -62% | 20.3 |
| 77 |  $GPCR | Structure Therapeutics Inc. | $232,123 | 0.2% | -69% | — |
| 78 |  $MEDP | Medpace Holdings, Inc. | $227,724 | 0.2% | +0% | 76.2 |
| 79 |  $TEM | Tempus AI, Inc. | $224,768 | 0.2% | NEW | 41.2 |
| 80 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $187,600 | 0.1% | NEW | — |
| 81 |  $PALI | PALISADE BIO, INC. | $183,920 | 0.1% | +0% | — |
| 82 |  $ENGN | enGene Therapeutics Inc. | $37,541 | 0.0% | NEW | — |
New Positions (14)
$ORKA Oruka Therapeutics, Inc.$4.0M$DFTX Definium Therapeutics, Inc.$3.7M$IRTC iRhythm Holdings, Inc.$3.1M$AVTX Avalo Therapeutics, Inc.$2.2M$CBIO CRESCENT BIOPHARMA, INC.$2.2M$PLSE PULSE BIOSCIENCES, INC.$1.9M$ATEC Alphatec Holdings, Inc.$1.6M$TMDX TransMedics Group, Inc.$1.5M$CVS CVS HEALTH Corp$1.3M$CNC CENTENE CORP$770,280$HUM HUMANA INC$497,299$TEM Tempus AI, Inc.$224,768$CRBP Corbus Pharmaceuticals Holdings, Inc.$187,600$ENGN enGene Therapeutics Inc.$37,541
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for SECTORAL ASSET MANAGEMENT INC including:
Track SECTORAL ASSET MANAGEMENT INC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for SECTORAL ASSET MANAGEMENT INC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: SECTORAL ASSET MANAGEMENT INC
13F Pro is an AI hedge fund tracker and stock research platform. For SECTORAL ASSET MANAGEMENT INC (SEC CIK: 1274413), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SECTORAL ASSET MANAGEMENT INC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.